FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to a peptide having the activity of a human SLURP-1 protein and its use for suppressing the growth of carcinomas and gliomas, to a pharmaceutical composition for suppressing the growth of carcinomas and gliomas containing the specified peptide, and to a method for suppressing the growth of carcinomas and gliomas in a subject suffering from these diseases.
EFFECT: obtaining a peptide with the activity of a human SLURP-1 protein to suppress the growth of carcinomas and gliomas.
8 cl, 6 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE HAVING LYNX1 PROTEIN ACTIVITY (EMBODIMENTS), PHARMACEUTICAL COMPOSITION FOR TREATING ANXIETY DISORDERS AND DEPRESSION OR CORRECTION OF COGNITIVE DISORDERS IN NEURODEGENERATIVE DISEASES, CONTAINING SAID PEPTIDE, AND METHOD OF TREATING AND CORRECTING SAID DISORDERS | 2020 |
|
RU2734649C1 |
| PEPTIDES AND PEPTIDOMIMETICS IN COMBINATION WITH CONTROL POINT INHIBITING AGENTS FOR TREATING CANCER | 2016 |
|
RU2739201C2 |
| PEPTIDES AND PEPTIDOMIMETICS FOR COMBINED USE AND TREATMENT IN A SUBPOPULATION OF PATIENTS WITH CANCER DISEASES | 2014 |
|
RU2732440C2 |
| IMPROVED PEPTIDE DRUGS FOR TREATMENT OF NASH AND OTHER DISORDERS | 2019 |
|
RU2790209C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| PEPTIDES AND THEIR USE IN TREATMENT OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH MUTANT p53 | 2017 |
|
RU2762089C2 |
| USE OF RECOMBINANT ANALOGUE OF WATER-SOLUBLE DOMAIN OF LYNX1 PROTEIN FOR CELL GROWTH INHIBITION BY CARCINOMA | 2019 |
|
RU2721129C1 |
| PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
| APPLICATION OF RECOMBINANT ANALOGUE OF HUMAN PROTEIN SLURP-1 IN COMBINATION WITH CYTOSTATICS OR PROTEASOME INHIBITOR PRODUCTS FOR INHIBITING GROWTH OF CARCINOMAS | 2020 |
|
RU2751132C1 |
